Cryoablation Combined with Programmed Cell Death Protein 1 Inhibitor Pembrolizumab for Advanced Non-Small Cell Lung Cancer
Chemotherapy · 2025
DOI: 10.1159/000545185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemotherapy, 2025. Verfasst von Li Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized, Cryosurgery. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Introduction
This study aims to evaluate the efficacy and safety of cryoablation combined with pembrolizumab treatment versus cryoablation alone in patients with advanced non-small cell lung cancer (NSCLC).
Methods
This retrospective study was conducted from February 2018 to October 2021. A total of 90 patients with NSCLC (AJCC stage IIIB/IV) were included, with 36 patients receiving cryoablation combined with pembrolizumab (group A) and 54 patients receiving cryoablation alone (group B). The primary outcome measures included objective response rate (ORR), overall survival (OS), and progression-free survival (PFS), immune responses, and adverse events serving as secondary endpoints. Risk factors for OS and PFS were identified using univariate and multivariate analyses.
Results
No treatment-related deaths were observed. Group A demonstrated a higher ORR (75.0% vs. 61.1%), longer median OS (28.1 months vs. 24.2 months), and longer median PFS (12.8 months vs. 8.4 months) compared to Group B. Additionally, group A showed significant increases in CD3+, CD4+, and CD8+ T cells, and elevated levels of interleukin-2, interleukin-6, TNF-β, and interferon-γ. The multivariate analysis showed the combination of cryoablation and pembrolizumab was an independent prognostic factor for OS and PFS.
Conclusions
Cryoablation combined with pembrolizumab significantly improves clinical outcomes in advanced NSCLC patients compared to cryoablation alone, highlighting the potential of this combination therapy in enhancing antitumor immunity and prolonging survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang, China.
- Department of General Surgery, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, China.
- Department of Oncology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, China.
Zitieren
APA
Wang, L., Yang, K., Xie, X., Wei, H., Wang, P., Wang, S., & Wang, P. (2025). Cryoablation Combined with Programmed Cell Death Protein 1 Inhibitor Pembrolizumab for Advanced Non-Small Cell Lung Cancer. Chemotherapy. https://doi.org/10.1159/000545185
Vancouver
Wang L, Yang K, Xie X, Wei H, Wang P, Wang S, et al. Cryoablation Combined with Programmed Cell Death Protein 1 Inhibitor Pembrolizumab for Advanced Non-Small Cell Lung Cancer. Chemotherapy. 2025. doi:10.1159/000545185
BibTeX
@article{Wang2025,
author = {Wang, Li and Yang, Kai and Xie, Xinxin and Wei, Hailiang and Wang, Pengli and Wang, Shaohui and Wang, Pengli},
title = {Cryoablation Combined with Programmed Cell Death Protein 1 Inhibitor Pembrolizumab for Advanced Non-Small Cell Lung Cancer},
journal = {Chemotherapy},
year = {2025},
doi = {10.1159/000545185}
}
EUVIMED